Bliss GVS Pharma Limited (BLISSGVS)
🎯 Key Takeaways
- Bliss GVS Pharma Limited is transitioning from a period of financial volatility to stabilized growth, marked by leadership changes and improving operational performance. The company has moved past a loss-making Q4FY24 and is now executing under new CEO Rahul Adakmol, with a focus on sustaining margin recovery and strategic expansion in regulated markets.
- Revenue declined 3.3% QoQ to ₹210 in Q3FY25.
- ⚠️ 1) Execution risk under new CEO Rahul Adakmol, as the company transitions leadership without clear long-term strategic targets disclosed. 2) Margin pr
📖 The Story
Bliss GVS Pharma Limited is transitioning from a period of financial volatility to stabilized growth, marked by leadership changes and improving operational performance. The company has moved past a loss-making Q4FY24 and is now executing under new CEO Rahul Adakmol, with a focus on sustaining margin recovery and strategic expansion in regulated markets.
📰 What's Happening
In July 2026, the board approved key leadership changes: Santosh Parab appointed as Additional Director, Rahul Adakmol named new CEO effective July 15, 2026, and Narsimha Kamath stepped down as CEO while retaining the role of Managing Director. These changes were formalized via video conference and reflect a structured succession plan. The appointments follow regulatory compliance and signal a shift in operational leadership aimed at reinforcing governance and execution focus.
Source: Stock Announcements
📊 Quarterly Results (₹ Cr)
| Metric | Q4FY23 | Q1FY24 | Q2FY24 | Q3FY24 | Q4FY24 | Q1FY25 | Q2FY25 | Q3FY25 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 185 | 160 | 212 | 201 | 198 | 184 | 218 | 210 |
| Operating Profit | 9 | 29 | 67 | 49 | 5 | 38 | 47 | 45 |
| OPM % | 3.4% | 15.2% | 25.7% | 21.8% | 14.3% | 18.7% | 19.1% | 14.2% |
| Net Profit | 3 | 14 | 43 | 29 | -5 | 22 | 26 | 26 |
| EPS | ₹0.34 | ₹1.41 | ₹4.06 | ₹2.64 | ₹-0.88 | ₹1.97 | ₹2.31 | ₹2.27 |
The company has shown sequential improvement in revenue and profitability, with Q3FY25 revenue at ₹210 crore and operating profit of ₹45 crore, up from ₹184 crore revenue and ₹38 crore OP in Q1FY25. After a weak Q4FY24 marked by a ₹5 crore operating profit and loss, performance rebounded strongly, indicating operational stabilization. Operating margins remain healthy at 14.2% in Q3FY25, supported by cost discipline and higher-margin product mix, despite a slight dip from prior quarters.
🔮 Management Outlook & What's Next
Management has not provided formal forward guidance in the latest filings, but the leadership transition to Rahul Adakmol as CEO suggests a focus on sustaining growth momentum and margin improvement. The board emphasized continuity in strategic direction while integrating new leadership, with the CEO transition expected to enhance execution capabilities in regulated markets.
Extracted from official company announcements. Not StockFin.ai's opinion.
⚖️ Peer Comparison — Pharmaceuticals & Biotechnology
| Company | MCap (₹ Cr) | P/E | ROCE | ROE | D/E |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | 4.51 L Cr | 41.3 | 20.3% | 15.1% | 0.03 |
| Divi's Laboratories Limited | 1.79 L Cr | 72.4 | 22.1% | 16.6% | 0.00 |
| Torrent Pharmaceuticals Limited | 1.49 L Cr | 80.1 | — | — | — |
| Cipla Limited | 1.16 L Cr | 25.4 | 19.4% | 14.6% | 0.00 |
| Dr. Reddy's Laboratories Limited | 1.12 L Cr | 20.0 | 19.7% | 16.6% | 0.12 |
| Lupin Limited | 1.04 L Cr | 36.2 | — | — | — |
| Mankind Pharma Limited | 1.03 L Cr | 49.2 | — | — | — |
| Zydus Lifesciences Limited | 1.02 L Cr | 22.5 | — | — | — |
| Aurobindo Pharma Limited | 87,806 | 25.3 | — | — | — |
| Laurus Labs Limited | 71,455 | 356.8 | — | — | — |
🔗 Peer Stock Analyses
⚠️ Risk Factors
1) Execution risk under new CEO Rahul Adakmol, as the company transitions leadership without clear long-term strategic targets disclosed. 2) Margin pressure risk from pricing competition in domestic formulation markets, despite current OPM stability. 3) Regulatory and compliance exposure due to global market dependencies, particularly in the US and EU, where pricing and supply chain dynamics remain volatile.
📋 Recent Filings
-
Announcement 15 July 2026Bliss GVS Pharma disclosed authorized contacts for material event reporting to exchanges, listing three KMPs and a company secretary with contact deta...
-
🟡 Board Meeting 3 July 2026The board approved the appointment of Santosh Parab as an additional non-executive director effective July 3, 2026, and Rahul Adakmol as CEO effective...
-
🟡 Board Meeting 3 July 2026No summary available
-
🟡 Board Meeting 3 July 2026Bliss GVS Pharma announced board approval of three key leadership changes effective July 2026: appointment of Santosh Parab as Additional Director, Ra...
-
🟡 Board Meeting 3 July 2026Bliss GVS Pharma announced board approval of three key changes: appointment of Santosh Parab as Additional Director effective July 3, 2026; appointmen...
-
Financial Results 29 June 2026Bliss GVS Pharma Limited announced that its trading window closes on July 1, 2026, ahead of the unaudited Q1 results release, restricting insiders fro...
-
🔴 Corporate Action 23 June 2026Bliss GVS Pharma announced that its shares will be closed for record on July 9-15, 2026, to determine eligibility for the 41st AGM on July 15, 2026, a...
-
🔴 annual report 23 June 2026Bliss GVS Pharma announced its 41st AGM on July 15, 2026, via video conference, with shareholders voting remotely. The meeting will adopt the audited ...
-
🟡 Board Meeting 23 June 2026Bliss GVS Pharma announced that its shares will be closed for record on July 9-15, 2026, to determine eligibility for the 41st Annual General Meeting ...
-
🟡 Board Meeting 19 June 2026Bliss GVS Pharma announced a final dividend of Re. 1 per share for FY 2025-26, payable after shareholder approval at the AGM on July 15, 2026. The com...
🧠 Analyst's Read
Bliss GVS Pharma is in a phase of post-turnaround stabilization, with improving financials and leadership changes aimed at reinforcing governance and growth. Investors should monitor execution under the new CEO, margin trends, and any updates on international market expansion or product pipeline developments in the coming quarters.
Based on filing content and financial data. Not a recommendation.
Read the full analysis
Quarterly trends, balance sheet, cash flow, peer comparison, and AI insights — sign up free to unlock.
Sign Up Free — Unlock Full Analysis2 free AI queries per day.
Data sourced from stock announcements. Analysis generated by StockFin.ai.
For informational purposes only — not investment advice. Updated 2026-07-15.
📡 Get AI alerts when BLISSGVS files new disclosures
Track BLISSGVS filings, board meetings, and corporate actions. Free email alerts at 5 PM.
Track BLISSGVS — FreeFree account · 2 AI queries/day
© 2026 StockFin.ai — AI-powered Indian stock research